NephroMAG: Uses, Dosage & Side Effects

What Is NephroMAG and What Is It Used For?

NephroMAG contains betiatide, also known as mercaptoacetyltriglycine or MAG3. Betiatide is a synthetic peptide that serves as a chelating agent — a molecule designed to bind tightly to the radioactive isotope technetium-99m (99mTc). When the contents of the NephroMAG kit are combined with sodium pertechnetate (99mTcO4−) solution from a molybdenum-99/technetium-99m generator, a radiolabeling reaction occurs. This produces technetium-99m mertiatide (99mTc-MAG3), a stable radiopharmaceutical complex that, once injected into the bloodstream, is selectively extracted by the kidneys and allows detailed imaging of renal function using a gamma camera.

The development of 99mTc-MAG3 represented a major advancement in nuclear medicine renal imaging. Prior to its introduction, the most commonly used radiopharmaceutical for dynamic renal studies was iodine-131 hippuran (ortho-iodohippurate, OIH), which served as the gold standard for measuring effective renal plasma flow (ERPF). However, iodine-131 had significant limitations: it emitted beta particles (increasing radiation dose), had suboptimal gamma energy for imaging with modern cameras, and required separate laboratory measurements for quantitative analysis. In the 1980s, researchers at Emory University and other institutions developed MAG3 as a technetium-99m–labeled alternative that could be imaged with standard gamma cameras while maintaining renal handling characteristics similar to OIH. Technetium-99m, with its ideal gamma energy of 140 keV and short half-life of 6 hours, provides excellent image quality with a significantly lower radiation dose to the patient.

After intravenous injection, 99mTc-MAG3 is rapidly extracted from the blood by the kidneys. Approximately 40–50% of the injected dose is extracted during a single pass through the renal circulation, compared to approximately 20% for 99mTc-DTPA (diethylenetriamine pentaacetic acid), which is cleared by glomerular filtration alone. The high extraction efficiency of MAG3 is due to its predominant clearance by active tubular secretion in the proximal renal tubules, which accounts for approximately 90–95% of its renal clearance. A small fraction (approximately 5–10%) is cleared by glomerular filtration. This dual mechanism, dominated by tubular secretion, results in higher kidney-to-background ratios and superior image quality compared to agents that rely solely on glomerular filtration.

During the imaging procedure, a gamma camera positioned behind the patient records the distribution and transit of 99mTc-MAG3 through the kidneys over time. This dynamic sequence produces time-activity curves (renograms) for each kidney, which provide quantitative information about several key aspects of renal function:

• Renal perfusion (blood flow): The initial phase of the renogram (first 1–2 minutes) reflects the arrival and distribution of the radiotracer within the renal vasculature, providing information about renal blood flow.
• Tubular uptake (function): The second phase (2–5 minutes) shows the accumulation of the radiotracer within the renal parenchyma, reflecting tubular extraction and concentration, which correlates with renal function.
• Excretion and drainage: The third phase (5–20+ minutes) demonstrates the washout of the radiotracer from the kidneys into the collecting system and bladder, reflecting urinary tract drainage and potential obstruction.

99mTc-MAG3 renal scintigraphy with NephroMAG is used in a wide range of clinical scenarios across nephrology, urology, and general medicine. The principal clinical indications include:

• Evaluation of suspected renovascular hypertension: In combination with an ACE inhibitor (captopril renography), MAG3 scintigraphy can identify hemodynamically significant renal artery stenosis by demonstrating changes in the renogram pattern after ACE inhibition.
• Assessment of urinary tract obstruction: Diuretic renography (MAG3 scan combined with intravenous furosemide) differentiates mechanical obstruction from non-obstructive dilatation (hydronephrosis) of the renal collecting system.
• Determination of differential (split) renal function: MAG3 scintigraphy accurately quantifies the relative contribution of each kidney to overall renal function, expressed as a percentage of total function. This is critical for surgical planning, such as before nephrectomy.
• Monitoring kidney transplant function: Serial MAG3 scans can detect complications following renal transplantation, including acute tubular necrosis (ATN), rejection, vascular compromise, or urine leak.
• Evaluation of congenital urinary tract anomalies in children: MAG3 is the preferred agent for renal imaging in pediatric patients due to its superior image quality at lower radiation doses. It is widely used to assess conditions such as vesicoureteral reflux, ureteropelvic junction (UPJ) obstruction, multicystic dysplastic kidney, and ectopic kidneys.
• Assessment of renal function in patients with impaired kidney function: Because MAG3 has a higher extraction efficiency than DTPA, it produces better images in patients with reduced glomerular filtration rate (GFR), including those with chronic kidney disease (CKD), making it the preferred agent when kidney function is compromised.

What Should You Know Before Using NephroMAG?

Contraindications

NephroMAG is contraindicated in patients with known hypersensitivity (allergy) to betiatide, to any of the excipients in the kit, or to any component of the radiolabeled preparation. Although allergic reactions to 99mTc-MAG3 are extremely rare, patients who have experienced a previous adverse reaction to this radiopharmaceutical should not receive it again without thorough evaluation by their nuclear medicine physician. Alternative renal imaging agents or modalities (such as 99mTc-DTPA, renal ultrasound with Doppler, or MR angiography) may be considered in such cases.

There are no absolute contraindications based on renal function — indeed, one of the advantages of 99mTc-MAG3 is its ability to produce diagnostic images even in patients with significantly impaired kidney function. However, the clinical justification for the procedure must always be assessed on an individual basis, weighing the expected diagnostic benefit against the radiation exposure, however minimal.

Warnings and Precautions

Before undergoing a NephroMAG renal scan, the following considerations should be discussed with your nuclear medicine physician or referring doctor:

• Hydration status: Adequate hydration is essential for optimal image quality and to minimize radiation dose to the bladder wall. Patients should be encouraged to drink at least 500 mL of water (approximately 2 glasses) in the 30–60 minutes before the scan and to continue drinking fluids after the procedure. Dehydrated patients may produce suboptimal images and receive a higher bladder radiation dose due to delayed urinary excretion.
• Current medications: Certain medications can affect renal function measurements obtained from MAG3 scintigraphy. In particular, ACE inhibitors (such as captopril, enalapril, or ramipril), angiotensin receptor blockers (ARBs), diuretics, and non-steroidal anti-inflammatory drugs (NSAIDs) may alter renal hemodynamics and should be discussed with the referring physician. In some protocols, such as captopril renography, specific medication adjustments are intentionally made as part of the diagnostic procedure.
• Allergic reactions: Although extremely rare, hypersensitivity reactions to radiopharmaceuticals can occur. Emergency resuscitation equipment and medications (including epinephrine, antihistamines, and corticosteroids) must be immediately available in all nuclear medicine departments where NephroMAG is administered.
• Radiation exposure: As with all nuclear medicine procedures, the use of NephroMAG involves exposure to ionizing radiation. While the effective dose from a standard adult MAG3 scan is very low (approximately 0.7–1.0 mSv), equivalent to a few months of natural background radiation, the investigation should only be performed when the expected diagnostic benefit outweighs the radiation risk. This principle is especially important in pediatric patients, where the administered activity should be adjusted according to the child’s body weight using the EANM/SNMMI pediatric dosing card.

Pregnancy and Breastfeeding

Radiopharmaceutical procedures should generally be avoided during pregnancy due to the potential radiation exposure to the developing fetus. If a NephroMAG renal scan is considered clinically essential during pregnancy, the nuclear medicine physician must carefully weigh the expected diagnostic benefit against the potential risk to the mother and fetus. When the procedure is deemed necessary, the administered activity should be kept as low as reasonably achievable (ALARA) while still obtaining diagnostically adequate images.

Women of childbearing potential should have a pregnancy test performed before the administration of any radiopharmaceutical. If there is any possibility of pregnancy, the investigation should be postponed or an alternative non-radioactive diagnostic method should be considered. If a patient discovers she is pregnant after a NephroMAG scan has been performed, the radiation dose to the fetus should be calculated and the patient counseled by a medical physicist.

If a NephroMAG scan is required during breastfeeding, the patient should be advised to interrupt breastfeeding for at least 4 hours after administration and to discard any milk expressed during this period. However, because the majority of the injected 99mTc-MAG3 is rapidly excreted in the urine, the amount secreted into breast milk is very small. The precise duration of breastfeeding interruption should be determined by the nuclear medicine physician based on the administered activity and current guidelines.

Use in Children

99mTc-MAG3 is widely used and approved for renal imaging in pediatric patients, including neonates and infants. In fact, MAG3 is the preferred renal imaging agent in children due to its superior extraction efficiency and image quality at lower doses compared to 99mTc-DTPA. The administered activity in pediatric patients must be adjusted according to body weight, typically using the EANM/SNMMI pediatric dosage card, which provides weight-based activity recommendations. Minimum administered activities are specified to ensure adequate image quality: the EANM recommends a minimum of 15–20 MBq for neonates, with scaled increases based on body weight.

For pediatric diuretic renography (used to evaluate suspected ureteropelvic junction obstruction), specific protocols exist that may differ from adult protocols in terms of the timing of diuretic administration, patient positioning, and image acquisition parameters. Pediatric nuclear medicine studies should be performed by or under the supervision of nuclear medicine physicians experienced in pediatric imaging.

Driving and Operating Machinery

There are no effects of NephroMAG on the ability to drive or operate machinery. The procedure is non-sedating and does not impair cognitive or motor function. Patients can typically resume normal activities, including driving, immediately after the scan. However, patients who have received sedation for the procedure (rare, and typically only in very young children) should follow standard post-sedation guidelines.

How Does NephroMAG Interact with Other Drugs?

Unlike therapeutic drugs that exert systemic pharmacological effects, NephroMAG is a diagnostic radiopharmaceutical administered as a single intravenous injection at sub-pharmacological doses. The amount of betiatide in a standard NephroMAG preparation is extremely small (typically 1 mg or less), and it does not produce any direct therapeutic or toxic effects at the doses used for diagnostic imaging. Consequently, traditional drug-drug interactions in the pharmacokinetic sense (affecting absorption, distribution, metabolism, or excretion of other medications) are not expected with NephroMAG.

However, several classes of medications can affect the renal physiological processes that MAG3 scintigraphy is designed to measure. These medications can alter renal blood flow, tubular function, or urinary drainage, potentially affecting the interpretation of scan results. Understanding these effects is critical for accurate diagnosis:

In the specialized protocol of captopril renography (also called ACE inhibitor renography), the interaction between ACE inhibitors and renal hemodynamics is deliberately exploited for diagnostic purposes. In patients with hemodynamically significant renal artery stenosis, the affected kidney maintains glomerular filtration by angiotensin II–mediated constriction of the efferent glomerular arteriole. When an ACE inhibitor is administered, this compensatory mechanism is blocked, causing a characteristic deterioration in the renogram pattern on the affected side. This diagnostic approach has a sensitivity and specificity of approximately 85–95% for detecting functionally significant renovascular hypertension when performed according to standardized protocols.

Similarly, diuretic renography uses the pharmacological effect of furosemide (a potent loop diuretic) to differentiate true mechanical obstruction of the urinary tract from non-obstructive dilatation (functional hydronephrosis). After the initial MAG3 renogram demonstrates delayed drainage, furosemide is administered intravenously. In non-obstructed kidneys, the radiotracer washes out promptly after diuretic administration; in obstructed kidneys, the radiotracer remains retained. The half-time of drainage (T½) after furosemide is a key quantitative parameter: T½ less than 10 minutes indicates no obstruction, T½ greater than 20 minutes suggests obstruction, and values between 10–20 minutes are equivocal.

What Is the Correct Dosage of NephroMAG?

NephroMAG is not a medication that patients self-administer. The radiolabeling, quality control, dose measurement, and administration are all performed by trained nuclear medicine personnel (radiopharmacists, nuclear medicine technologists, and physicians) in a controlled clinical environment. The dosage of 99mTc-MAG3 is expressed in megabecquerels (MBq), a unit of radioactivity, rather than in milligrams. The chemical mass of betiatide in the injected preparation is negligible from a pharmacological perspective.

Adults

The preparation process for NephroMAG involves adding sodium pertechnetate (99mTcO4−) solution, freshly eluted from a molybdenum-99/technetium-99m generator, to the NephroMAG vial. The vial is then heated in a boiling water bath for approximately 10 minutes to complete the radiolabeling reaction. After cooling, the preparation must undergo quality control testing to verify radiochemical purity (typically ≥90–95% of the technetium-99m must be bound to MAG3) before it can be administered to patients. The prepared radiopharmaceutical has a limited shelf life (typically 4–6 hours after preparation) and must be used within this timeframe.

The injection technique is important for accurate diagnostic results. 99mTc-MAG3 is administered as a rapid intravenous bolus injection into an antecubital vein (or other suitable peripheral vein). A tight, compact bolus is essential for accurate assessment of renal perfusion in the first-pass phase. The injection should be performed with the patient already positioned under or in front of the gamma camera, and image acquisition should begin simultaneously with or immediately before the injection. The total injection volume is typically small (less than 1–2 mL), followed by a saline flush.

Children

Pediatric dosing of 99mTc-MAG3 is weight-based and follows the EANM/SNMMI pediatric dosing guidelines. The administered activity is calculated using a baseline adult activity multiplied by a weight-based fraction from the dosing card. As a general guide:

Children should be well hydrated before the procedure. For infants who cannot drink adequate fluids voluntarily, intravenous hydration may be used. Bladder catheterization is occasionally required in young children who cannot void on command, to ensure accurate assessment of renal drainage.

Elderly Patients

No dose adjustment is required for elderly patients based solely on age. The standard adult activity range applies. However, elderly patients may have reduced renal function, which can affect the appearance and quantitative results of the scan. The nuclear medicine physician will interpret the images in the context of the patient’s age and baseline renal function. Adequate hydration is particularly important in elderly patients, who may be at increased risk of dehydration.

Patients with Renal Impairment

No dose adjustment is required for patients with renal impairment. In fact, 99mTc-MAG3 is the preferred renal imaging agent in patients with reduced kidney function because its high tubular extraction efficiency produces diagnostically useful images even when the GFR is significantly reduced. However, in patients with severe renal failure, the clearance of the tracer will be delayed, the kidney-to-background ratio may be reduced, and extended imaging times (30–60 minutes or longer) may be necessary to adequately assess drainage patterns.

Overdose

Because the administered activity of 99mTc-MAG3 is carefully measured and calibrated before each injection, accidental overdose is extremely unlikely in routine clinical practice. In the event of an inadvertent administration of a significantly higher-than-intended activity, the radiation dose to the patient will be proportionally increased but is unlikely to cause deterministic radiation effects (tissue damage) even at several times the intended dose. The primary concern would be increased radiation exposure to the kidneys and bladder. Management would include encouraging vigorous fluid intake and frequent voiding to accelerate renal clearance of the radiotracer, thereby reducing the radiation dose to the bladder wall. The patient’s radiation dose should be calculated by a medical physicist and documented.

What Are the Side Effects of NephroMAG?

99mTc-MAG3 has an excellent safety profile established over more than three decades of worldwide clinical use and millions of administered doses. The radiopharmaceutical is administered at sub-pharmacological mass doses (typically less than 1 mg of betiatide), which means it does not produce the pharmacological side effects typically associated with therapeutic medications. The vast majority of patients undergoing a MAG3 renal scan experience no adverse effects whatsoever.

Systematic post-marketing surveillance data and published literature reviews have confirmed the rarity of adverse reactions to 99mTc-MAG3. The following categorization of potential adverse effects is based on available clinical data and regulatory pharmacovigilance reports:

It is important to distinguish between adverse reactions to the radiopharmaceutical itself and the effects of radiation exposure. The radiation dose from a standard 99mTc-MAG3 renal scan is very low. For a typical adult study using 100–185 MBq of 99mTc-MAG3, the estimated absorbed radiation doses to key organs are:

If you experience any symptoms during or after a NephroMAG renal scan that concern you, inform the nuclear medicine staff immediately. While adverse reactions are extremely uncommon, the nuclear medicine department is equipped to manage any complications should they arise. Patients with a history of prior adverse reactions to radiopharmaceuticals or iodinated contrast media should inform the nuclear medicine team before the procedure, even though cross-reactivity is not expected.

How Should You Store NephroMAG?

NephroMAG is a hospital-use product that is stored, prepared, and administered entirely within the nuclear medicine department. Patients never handle or store the product themselves. However, understanding the storage requirements provides context for the quality and safety standards that govern radiopharmaceutical handling.

Before Radiolabeling (Kit Storage)

• Store the NephroMAG kit at 2–8 °C (in a refrigerator)
• Protect from light
• Do not freeze
• Store in the original outer packaging
• Check the expiration date before use — do not use after the expiry date printed on the vial and carton
• The kit contains lyophilized (freeze-dried) powder that is white to off-white in appearance

After Radiolabeling (Prepared Radiopharmaceutical)

• Store at room temperature (15–25 °C) in an appropriately shielded lead container
• Use within 4–6 hours of preparation (exact shelf life is specified in the product documentation and depends on the specific formulation)
• The reconstituted solution should be clear and colorless to slightly yellow; do not use if the solution is cloudy, discolored, or contains visible particles
• Label the shielded container with the preparation time, activity at calibration, expiry time, and patient information (if pre-drawn into a syringe)
• Handle in accordance with local radiation protection regulations and institutional radioactive waste management procedures

Disposal

All unused NephroMAG product, expired kits, used syringes, vials, and contaminated materials must be disposed of as radioactive waste in accordance with national and local regulations for radioactive material disposal. Technetium-99m has a short physical half-life (6.02 hours), meaning that most radioactive waste can be allowed to decay in storage for a minimum of 10 half-lives (approximately 60 hours or 2.5 days) before disposal as conventional pharmaceutical waste, subject to confirmation of adequate decay by radiation monitoring and institutional policy.

What Does NephroMAG Contain?

NephroMAG is supplied as a kit containing one or more vials of lyophilized (freeze-dried) powder. Each vial contains the following components:

Active Ingredient

• Betiatide (mercaptoacetyltriglycine, MAG3): approximately 1 mg per vial. Betiatide is the chelating peptide that binds technetium-99m to form the diagnostic radiopharmaceutical 99mTc-mertiatide. It is a synthetic tripeptide derivative with a thiol (sulfhydryl) group that coordinates with the technetium atom during the radiolabeling reaction.

Excipients

• Stannous chloride dihydrate (SnCl2·2H2O): A reducing agent essential for the radiolabeling reaction. Stannous (tin) ions reduce pertechnetate (99mTcO4−, technetium in oxidation state +7) to a lower oxidation state that can be chelated by betiatide. The amount of stannous chloride is carefully controlled to optimize labeling efficiency while minimizing free reduced hydrolyzed technetium (colloid).
• Sodium tartrate dihydrate: Acts as a stabilizer and pH buffer. It helps maintain the appropriate chemical conditions for the radiolabeling reaction and stabilizes the final radiopharmaceutical complex.
• Lactose monohydrate: Used as a bulking agent (lyoprotectant) to provide appropriate physical properties to the lyophilized cake, facilitating reconstitution and ensuring consistent kit performance.
• Nitrogen atmosphere: The vial headspace is purged with nitrogen gas to create an inert atmosphere that prevents oxidation of the stannous ions, which would impair the radiolabeling reaction. Maintaining this nitrogen atmosphere is critical for kit performance, which is why vials must not be opened or punctured before use.

After radiolabeling, the injected preparation also contains technetium-99m (99mTc) from the sodium pertechnetate solution used for reconstitution. Technetium-99m is a metastable nuclear isomer of technetium-99 that decays by isomeric transition, emitting a 140 keV gamma ray that is detected by the gamma camera. Its half-life of 6.02 hours provides an optimal balance between sufficient time for imaging and rapid decay to minimize patient radiation exposure.

The final reconstituted solution for injection is sterile, pyrogen-free, and isotonic. It has a pH of approximately 5.0–6.5, which is well-tolerated for intravenous injection. The total volume of the injection is typically 1–5 mL depending on the required activity and the specific reconstitution volume used.